Mesoblast Presents Corporate Update at 26TH Annual Credit Suisse Healthcare Conference
November 09, 2017 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today presented a corporate update at the 26th Annual Credit Suisse Healthcare...
Clinical Trial of Mesoblast’s Cell Therapy in End-Stage Heart Failure Patients Completes Enrollment
September 28, 2017 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that a multi-center team of researchers led by Icahn School of...
Mesoblast Presents Corporate Updates at Global Healthcare Conferences
September 25, 2017 07:26 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the company will this week present corporate updates at the...
Mesoblast Operational Highlights and Financial Results for the Fourth Quarter and for the Year Ended 30 June 2017
August 29, 2017 18:42 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today reported its consolidated financial results and operational highlights for the...
Mesoblast Outlines Potential Pathway to Accelerated Market Entry for MPC-150-IM in Advanced Chronic Heart Failure
August 23, 2017 06:00 ET
|
Mesoblast Limited
Advanced chronic heart failure (CHF) in patients with New York Heart Association (NYHA) Class III/IV is a major unmet medical need due to the high rates of morbidity and mortality despite existing...
Positive Trial Results of Mesoblast Cell Therapy in Post-Traumatic Osteoarthritis Published In Arthritis Research & Therapy
August 16, 2017 06:00 ET
|
Mesoblast Limited
Over 250,000 Anterior Cruciate Ligament (ACL) tears occur annually in the United States alone, mostly in young, physically active adults1 By 1 year, more than 30% have radiographic evidence of knee...
Mesoblast Rheumatoid Arthritis Trial Results Presented at EULAR Annual European Congress of Rheumatology
June 22, 2017 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, June 22, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) announced that results from the randomized, placebo-controlled 48-patient Phase 2 trial...
Mesoblast Operational Highlights and Financial Results for the Period Ended March 31, 2017
May 24, 2017 18:15 ET
|
Mesoblast Limited
Melbourne, Australia and New York, May 24, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today provided the market with operational highlights and financial results for the...
Successful Interim Analysis of Efficacy Endpoint in Mesoblast’s Phase 3 Trial for Chronic Heart Failure
April 10, 2017 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, April 10, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the Phase 3 trial of its allogeneic mesenchymal...
Mesoblast Receives A$3.7 Million From the Australian Government for Research and Development Activities
April 06, 2017 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, April 06, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has received A$3.7 million from the Australian Government for...